MESNA 2 Mercaptoethanesulfonate Attenuates.13
MESNA 2 Mercaptoethanesulfonate Attenuates.13
net/publication/372945387
CITATIONS READS
0 23
8 authors, including:
Some of the authors of this publication are also working on these related projects:
All content following this page was uploaded by Ahmet Ozer Sehirli on 06 August 2023.
Abstract
Pharmacology, Faculty of
Pharmacy, 1Department
result of the increased formation of various reactive oxygen metabolites,
of Pharmacology, Faculty infiltration of inflammatory cells, interstitial edema, cellular dysfunction, and
of Dentistry, 2Department tissue death. Aim: The study aimed to investigate the cytoprotective effect of
nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 08/06/2023
DOI: 10.4103/njcp.njcp_654_22 How to cite this article: Mercan M, Şehirli AÖ, Gültekin Ç, Chukwunyere U,
Sayıner S, Gençosman S, et al. MESNA (2‑mercaptoethanesulfonate) attenuates
brain, heart, and lung injury induced by carotid ischemia‑reperfusion in
rats. Niger J Clin Pract 2023;26:941-8.
© 2023 Nigerian Journal of Clinical Practice | Published by Wolters Kluwer ‑ Medknow 941
Mercan, et al.: Effects of MESNA on carotid ischemia‑reperfusion in rats
increases the levels and activation of inflammatory I/R group was exposed to ischemia‑reperfusion and
cytokines such as tumor necrosis factor‑alpha (TNF‑α) treated with normal saline (intraperitoneally). The two
and Interleukin‑1‑beta (IL‑1 β), and proteolytic MESNA‑treated groups received MESNA (Uromitexan
enzymes such as matrix metalloproteinase (MMP), 75 mg/kg and 150 mg/kg, i.p.; Baxter, Germany),
leading to inflammation and degeneration of tissues.[3] respectively, 30 minutes before ischemia‑reperfusion.
It is well known that the acute inflammatory response The MESNA dose used in this study was modified based
leads to tissue damage through the production and on previous studies.[8,11,20]
Downloaded from http://journals.lww.com/njcp by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
saline. The samples were placed in 10% formaldehyde (75 and 150 mg/kg) (P < 0.05–0.01). However,
and routinely processed by embedding in paraffin. there was no significant difference between the
Tissue sections (5–6 mm) were stained with hematoxylin sham and either MESNA treatment groups, nor
and eosin and examined under a light microscope. An between the I/R + MESNA (75 and 150 mg/kg)
experienced histopathologist who was blinded to the groups (P > 0.05) [Table 1].
study design performed the histologic assessments. Effects of MESNA on serum malondialdehyde levels
Downloaded from http://journals.lww.com/njcp by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
compared using one‑way analysis of variance (ANOVA) in serum MDA levels (P < 0.001). The I/R + MESNA
followed by Tukey’s post hoc test. Values of P < 0.05 (75 and 150 mg/kg) groups showed no significant
were considered statistically significant. differences in MDA levels compared with the
sham group (P > 0.05). Serum MDA levels were
Results not significantly different between both MESNA
Biochemical results (75 and 150 mg/kg) groups (P > 0.05) [Table 2].
Effects of MESNA on serum enzyme activities Effects of MESNA on serum matrix metalloproteinases
Analysis of serum levels ALP, AST, ALT, and (MMP‑1, ‑2, ‑8) and tissue inhibitor of metalloprotease‑1
LDH levels in the carotid I/R group showed a (TIMP‑1) expression
highly significant increase compared with the sham, In the carotid I/R group, the serum levels of
I/R + MESNA (75 mg/kg), and I/R + MESNA MMP (‑1, ‑2, ‑8) and TIMP‑1 levels increased
(150 mg/kg) groups (P < 0.05–0.001). The carotid significantly compared to the other groups
I/R‑induced increase in serum enzyme levels (p < 0.05–0.0001). After treatment with MESNA
significantly decreased after treatment with MESNA (75 mg/kg and 150 mg/kg), serum levels of
Table 1: Serum levels of alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine transaminase (ALT),
and lactate dehydrogenase (LDH)
Sham Carotid I/R I/R + MESNA 75 mg/kg I/R + MESNA 150 mg/kg
ALP (U/L) 60.67±7.86 109±10.03*** 77.75±2.01# 68.37±6##
AST (U/L) 129±4.40 161.1±5.97** 129.8±6.69 ##
132.4±5.48##
ALT (U/L) 27.18±1.45 114.4±26.03** 35.35±7.40 ##
36.62±7.51##
LDH (U/L) 1360±153.7 2833±400.2** 1593±141.2 ##
1848±160.2#
Values are expressed as mean±standard error (n=6); **P<0.01, ***P<0.001 vs. sham; # P<0.05, ##P<0.01, vs. carotid I/R
Table 3: Serum matrix metalloproteinases (MMP‑1, ‑2, ‑8) and tissue inhibitor of metalloprotease‑1 (TIMP‑1) levels
Downloaded from http://journals.lww.com/njcp by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
Sham Carotid I/R I/R + MESNA 75 mg/kg I/R + MESNA 150 mg/kg
MMP‑1 (pg/mL) 1.51±0.15 3.82±0.19**** 2.49±0.28## 2.30±0.20###
MMP‑2 (pg/mL) 30.93±5.90 56.32±6.0** 28.69±2.27 ##
22.61±1.57###
MMP‑8 (pg/mL) 72.39±7.71 190.7±43.07** 96.48±4.75 #
82.79±4.74#
nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 08/06/2023
Table 4: Serum tumor necrosis factor‑alpha (TNF‑α) and Interleukin‑1‑beta (IL‑1β) levels
Sham Carotid I/R I/R + MESNA 75 mg/kg I/R + MESNA 150 mg/kg
TNF‑α (pg/mL) 13.36±3.10 34.17±6.17** 19.69±1.58# 8.59±1.61###
IL‑1β (pg/mL) 154.1±17.35 332.2±25.15**** 146.3±16.89 ####
113.4±15.79####
Values are expressed as mean±standard error (n=6); **P<0.01, ****P<0.0001 vs. sham; P<0.05, P<0.001, P<0.0001 vs. carotid I/R
# ### ####
Table 5: Effects of ischemia‑reperfusion and its treatment with MESNA on brain tissue
Sham Carotid I/R I/R + MESNA 75 mg/kg I/R + MESNA 150 mg/kg
Brain neutrophil layout 0.28±0.05 2.35±0.19**** 1.43±0.05****#### 1.23±0.04****####
Brain capillar intensity 0.25±0.02 2.4±0.07**** 1.7±0.05****####
1.23±0.04****####
Neuronal degeneration 0.33±0.05 2.9±0.07**** 2.55±0.04**** ##
2.26±0.06****####
Values are expressed as mean±standard error (n=6); ****P<0.0001 vs. sham; P<0.01, P<0.0001 vs. carotid I/R
## ####
Table 6: Effects of ischemia‑reperfusion and its treatment with MESNA on lung tissue
Sham Carotid I/R I/R + MESNA 75 mg/kg I/R + MESNA 150 mg/kg
Lung congestion 0.61±0.06 2.95±0.08**** 2.11±0.15****#### 1.78±0.08****####
Alveolar degeneration 0.51±0.06 2.86±0.18**** 2.21±0.14****#### 1.68±0.08****####++
Interstitial oedema 0.65±0.07 2.96±0.06**** 2.13±0.66****#### 1.61±0.13****####++
Values are expressed as mean±standard error (n=6); ****P<0.0001 vs. sham; ####P<0.0001 vs. carotid I/R; ++P<0.01: MESNA 75 vs.
MESNA 150 mg/kg
Downloaded from http://journals.lww.com/njcp by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
Table 7: Effects of ischemia‑reperfusion and its treatment with MESNA on heart tissue
Sham Carotid I/R I/R + MESNA 75 mg/kg I/R + MESNA 150 mg/kg
nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 08/06/2023
a b a b
c d c d
Figure 3: Microscopic examination of lung tissues. (a) Sham Figure 4: Microscopic examination of heart tissues. (a) sham group:
group: regular alveolar structure (arrows) and interstitial space, regular arrangement of cardiomyocytes and capillaries (*); (b) carotid
bronchiole (*); (b) carotid I/R group: severe and diffuse interstitial I/R group: severe congestion of the capillaries (arrow), cytoplasmic
edema (arrowhead) and capillary obstruction in hemorrhagic areas and disorganization in cardiomyocytes (*); (c) I/R + MESNA 75 mg/kg
decreased alveolar spaces (arrows); (c) I/R + MESNA 75 mg/kg group: group: reduced capillary congestion (arrowhead) and relative organization
improved alveolar structures (arrows) by regression of the interstitial of cardiomyocytes (*); (d) I/R + MESNA 150 mg/kg group: marked
edema (arrowhead) and bronchioles (*); (d) I/R + MESNA 150 mg/kg regression of capillary congestion (arrow) and regular pattern of
group: recovery highlighted in alveolar structure (arrows) and reduced cardiomyocytes (*). (H.E, Bar 50 µm)
interstitial edema (arrowheads). (H.E, Bar 50 µm)
Heart morphometric result
these changes caused by MESNA 75 and 150 mg/kg Heart congestion, cardiomyocyte degeneration, and
were not significantly different when both groups were inflammation scores were significantly higher in the
compared (P > 0.05) [Table 5]. carotid I/R group than in the sham group (P < 0.0001).
Lung morphometric result Treatment with MESNA especially high dose
Lung congestion, alveolar degeneration, and interstitial (150 mg/kg) decreased heart histological feature
edema scores were significantly higher in the carotid scores compared with the sham and carotid I/R
I/R group than in the sham group (P < 0.0001). groups (P < 0.05–0.0001). In addition, cardiomyocyte
Treatment with MESNA (75 mg/kg and 150 mg/kg) degeneration scores were significantly decreased more
significantly decreased the values of lung histological with MESNA 150 mg/kg than with MESNA 75 mg/kg
features compared with the sham and carotid I/R (P < 0.01) [Table 7].
groups (P < 0.0001). In addition, alveolar degeneration Microscopic presentation of lungs, heart, and brain
and interstitial edema scores were more significantly sections from the treated groups
decreased with MESNA 150 mg/kg than with MESNA Light microscopy examination of lung tissue in the
75 mg/kg (P < 0.01) [Table 6]. sham group showed a consistent alveolar structure
and interstitial space [Figure 3a]. In the carotid IR of proteolytic enzymes as well as proinflammatory
group, diffuse and severe hemorrhage with edema in cytokines, resulting in damage to brain, heart, and lung
interstitial spaces was observed. Besides, distended tissue.
alveolar walls and decreased alveolar space due to
Lipid peroxidation caused by oxidative degradation of
edema as well as severe leukocytes accumulation
polyunsaturated fatty acids in membranes is thought to
were observed [Figure 3b]. In IR + MESNA
play a key role in disrupting cell membrane integrity
75 mg/kg group, due to the regression of hemorrhage
Downloaded from http://journals.lww.com/njcp by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
and pro‑inflammatory gene expression. J Biol Chem NLRP‑mediated inflammatory response inhibition. Clin Exp
2003;278:43807‑17. Pharmacol Physiol 2021;48:1103‑10.
16. Collard CD, Lekowski R, Jordan JE, Agah A, Stahl GL. 33. Liu C, Chu D, Kalantar-Zadeh K, George J, Young HA, Liu G.
Complement activation following oxidative stress. Mol Immunol Cytokines: From clinical significance to quantification. Adv Sci
1999;36:941–8. 2021;8:2004433.
17. Duehrkop C, Rieben R. Ischemia/reperfusion injury: Effect of 34. Duan L, Ma Y, Chi J, Wang X, Wesley AJ, Chen X. The
simultaneous inhibition of plasma cascade systems versus specific regulatory role of immunosuppressants on immune abnormalities
complement inhibition. Biochem Pharmacol 2014;88:12–22. in acute pancreatitis. Biomed Rep 2014;2:193–8.
Downloaded from http://journals.lww.com/njcp by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AW
18. Ypsilantis P, Tentes I, Lambropoulou M, Anagnostopoulos K, 35. Gonçalves RL, Cunha FV, Sousa‑Neto BP, Oliveira LS,
Papadopoulos N, Kortsaris A, et al. Prophylaxis with mesna Lopes ME, Rezende DC, et al. α‑Phellandrene attenuates
prevents oxidative stress induced by ischemia reperfusion in tissular damage, oxidative stress, and TNF‑α levels on acute
the intestine via inhibition of nuclear factor‑kappaB activation. model ifosfamide‑induced hemorrhagic cystitis in mice.
nYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC4/OAVpDDa8KKGKV0Ymy+78= on 08/06/2023